Insilico Medicine and Qilu Pharmaceutical signed a collaboration worth up to $120 million to co-develop AI-enabled small molecules targeting cardiometabolic disease. The deal pairs Insilico’s generative and screening platforms with Qilu’s development and regional commercialization capabilities, creating a joint path for discovery through early development. Qilu’s commitment positions the Shanghai-based pharma to accelerate its cardiometabolic pipeline while giving Insilico a sizable near-term commercial partner for AI-designed candidates. Financial terms include upfront payments and milestone structures; the alliance follows a string of similar AI-driven drug discovery partnerships announced by Insilico in recent months.